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Background: The purpose of this study was to evaluate the technical feasibility of an image-guided intensity
modulated radiotherapy (IG-IMRT) using involved-field technique to perform a hypofractionated schedule for
patients with locally advanced or recurrent pancreatic cancer.
Methods: From May 2009 to November 2011, 12 patients with locally advanced or locally recurrent pancreatic cancer
received hypofractionated CCRT using TomoTherapy Hi-Art with concurrent and sequential chemotherapy at Seoul St.
Mary’s Hospital, the Catholic University of Korea. The total dose delivered was 45 Gy in 15 fractions or 50 Gy in 20
fractions. The target volume did not include the uninvolved regional lymph nodes. Treatment planning and delivery were
performed using the IG-IMRT technique. The follow-up duration was a median of 31.1 months (range: 5.7-36.3 months).
Results: Grade 2 or worse acute toxicities developed in 7 patients (58%). Grade 3 or worse gastrointestinal and
hematologic toxicity occurred in 0% and 17% of patients, respectively. In the response evaluation, the rates of partial
response and stable disease were 58% and 42%, respectively. The rate of local failure was 8% and no regional failure was
observed. Distant failure was the main cause of treatment failure. The progression-free survival and overall survival
durations were 7.6 and 12.1 months, respectively.
Conclusion: The involved-field technique and IG-IMRT delivered via a hypofractionated schedule are feasible for patients
with locally advanced or recurrent pancreatic cancer.
Keywords: Unresectable pancreatic cancer, Hypofractionated radiotherapy, Image-guided, Intensity-modulated
radiotherapyBackground
Pancreatic cancer is the fourth leading cause of cancer
death in the United States and the fifth leading cause of
cancer death in South Korea [1]. Surgery remains the only
potentially curative treatment modality for pancreatic can-
cer, with a 5-year survival rate of approximately 20% [2].
However, according to the Surveillance, Epidemiology and* Correspondence: hsjang11@catholic.ac.kr
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reproduction in any medium, provided the orEnd Results database, 26% of pancreatic cancer cases are
locally advanced at the time of diagnosis, with a 5-year
survival rate of 8.7% [3].
The current standard treatment of unresectable locally
advanced pancreatic cancer is either concurrent chemor-
adiation (CCRT) or chemotherapy alone. The clinical
results from these treatments showed a poor median
survival of 8–14 months [4-16].
Recently, there have been considerable technological
advances in the field of radiation oncology such as image-
guided, intensity-modulated radiotherapy (IG-IMRT). Due. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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vers a higher dose to the target volume can be achieved
with a reduction of the dose delivered to the surround-
ing normal tissues.
As gemcitabine is known as a potent radiosensitizer, it
was combined with radiotherapy (RT) in several studies.
However, the maximal tolerated dose of radiation that
could be administered with concurrent full-dose gemci-
tabine was 36 Gy, which was not sufficient for adequate
local control and the clinical outcomes were suboptimal
[16,17].
We hypothesized that hypofractionated CCRT would
improve the local control rate and shorten the treatment
duration, which would facilitate the delivery of systemic
chemotherapy earlier as compared to conventional RT.
Further, IG-IMRT would permit the delivery of a high
dose of radiation without an increase in gastrointestinal
toxicity. In the present study, we aimed to evaluate the
technical feasibility of an IG-IMRT involved-field tech-
nique to perform a hypofractionated schedule in patients
with locally advanced or recurrent pancreatic cancer.
Methods
Patients
Between May 2009 and November 2011, 12 patients with
unresectable locally advanced or recurrent pancreatic
cancer received hypofractionated CCRT using Tomo
Therapy Hi-Art at Seoul St. Mary’s Hospital, the Catholic
University of Korea. The patients’ data were retrospect-
ively reviewed following institutional review board approval
(IRB of Seoul St. Mary's Hospital, The Catholic University
of Korea, Reference number: KC11RISI0454). Written
informed consent was obtained from the patient for publi-
cation of this report and any accompanying images. The
inclusion criteria for this study were as follows: 1) a histo-
logically confirmed adenocarcinoma of the pancreas; 2) an
unresectable locally advanced disease at the time of diag-
nosis or locally recurrent disease after a curative resection;
3) patient age >18 years; 4) an Eastern Cooperative Oncol-
ogy Group performance status of 0, 1, or 2; 5) an adequate
bone marrow functional reserve (leukocytes > 3000/μL, an
absolute neutrophil count > 1500/μL and a platelet
count > 100000/μL); and 6) an adequate hepatic and
renal functional reserve (total bilirubin < 1.5 × the in-
stitutional limits, aspartate aminotransferase/alanine
aminotransferase < 2.5 × the institutional limits and
creatinine within the institutional limits). Patients were
excluded if they had distant metastases or resectable
disease or if they had previously received RT in the
upper abdomen.
All patients were evaluated by a multidisciplinary team.
The pretreatment evaluation included a medical history,
physical examination, complete blood count (CBC), blood
chemistry panel, assessment of carbohydrate antigen (CA19–9) levels, chest X-ray and a pancreas-protocol com-
puted tomography (CT). Magnetic resonance imaging
(MRI) and positron emission tomography-computed tom-
ography (PET-CT) were performed in selected patients.
Tumors were considered unresectable if they demon-
strated any of the following features: 1) a superior mesen-
teric artery or celiac encasement greater than 180°; 2) an
unreconstructable superior mesenteric vein/portal occlu-
sion; or 3) aortic invasion.
Radiotherapy
For simulation and treatment, patients were immobilized
using the BodyFix system (Medical Intelligence, GmbH,
Schwabmunchen, Germany), in which the abdomen was
compressed with low pressure using foil. A spiral CT scan
was then performed with oral and intravenous contrast
and a 2.5 mm slice thickness, and 4-dimensional (4D) CT
was also performed to assess the movement of the target
during respiration using a SOMATOM (Siemens, Berlin,
Germany) CT scanner and an ANZAI HW Respiratory
Gating System (Siemens, Berlin, Germany).
The gross tumor volume (GTV) was defined as the
gross disease identified in the planning CT. For each pa-
tient, a 4D CT was performed to determine the adequate
margin for the planning target volume (PTV). We mea-
sured respiration-induced tumor movement quantita-
tively using the syngo Multi-Modality Workplace (syngo
InSpace4D, Siemens, Erlangen, Germany) and then cre-
ated the ITV by adding 7–12 mm to the GTV according
to this measurement of the tumor movement. The PTV
was generated by adding 3 mm to the ITV with allowing
an asymmetric margin expansion in order to reduce ir-
radiation to the stomach, duodenum, and small intes-
tine. The uninvolved regional lymph nodes (LNs), which
were traditionally included in conventional RT, were not
included in the target volume. This was due to the rela-
tively lower rate of regional failure and our concern
about an increased risk of unacceptable toxicities to the
surrounding normal tissue, which would have occured if
these areas were included in the target volume.
We prescribed 45 in 15 fractions or 50 Gy in 20 frac-
tions to 95% of the PTV. Because of concerns of the
acute or late gastrointestinal toxicities, we prescribed
45 Gy in 15 fractions to the small PTV and 50 Gy in 20
fractions to the large PTV. The dose constraints of the
normal tissue were also used for treatment planning.
The volume of liver receiving >25 Gy should be <60%
and the mean dose to the liver should be <30 Gy. The
volume of each kidney receiving >18 Gy should be <33%
and the mean dose to the each kidney should be <16 Gy.
The maximal dose to a 2 cc volume (D2cc) of the spinal
cord, stomach, small intestine, large intestine, and heart
should be <42, 45, 45, 48, and 45 Gy, respectively.
Treatment planning was performed using the built-in
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was used for the TomoTherapy Hi-Art (Figure 1). We
evaluated the dose volume histograms (DVHs) and the
dose distributions slice by slice. We then approved the
treatment plan if the tumor coverage was adequate and
the doses to the surrounding normal tissue were within
the proper levels.
Radiation was delivered using a TomoTherapy Hi-
Art. Prior to the actual beam delivery, megavoltage
cone-beam CT was performed at the time of every
treatment session. The patients’ set-up and position
were corrected with automated image registration, and
the anatomical accuracy was always evaluated by a ra-
diation oncologist.
Chemotherapy
Chemotherapy was administered concurrently with RT
and then sequentially. For CCRT, 12 patients were treated
with 5-fluorouracil (5-FU) (600 mg/m2/week, weekly).
After completing CCRT, 10 patients were treated with
gemcitabine (1000 mg/m2/week, 3 weeks on and 1 week
off) until disease progression and one patient was
treated with 5-FU/leucovorin (5-FU: 425 mg/m2/day,
LV: 20 mg/m2/day, days 1–5, monthly). One patient
was not treated with chemotherapy after CCRT due to
a poor performance status. An average of 4.5 cycles
(range: 3–6 cycles) of chemotherapy were administered
prior to tumor progression.Figure 1 A comparison of the isodose distribution and dose-volum
the 4-field technique. The isodose lines reading from lowest to highes
(A) and IMRT planning (B).Response and follow-up evaluation
All patients were examined during CCRT and every
2–4 months after the completion of CCRT by a radi-
ation oncologist and a medical oncologist. A physical
examination, CBC, blood chemistry panel, assessment
of CA 19–9 levels and pancreas-protocol CT were per-
formed at every visit. MRI, PET-CT and esophagogastro-
duodenoscopy (EGD) were optionally performed.
Tumor response and disease progression were evalu-
ated using the Response Evaluation Criteria In Solid
Tumors version 1.1 and the toxicities were evaluated
using the Common Terminology Criteria for Adverse
Events version 3.1. The co-primary end-points were the
toxicity and local response. The secondary end-points
were the time to progression (TTP), progression-free
survival (PFS) and overall survival (OS).
Statistical analysis
Statistical analysis was conducted using SPSS version 12.0
software (SPSS Inc., Chicago, IL) and a p value <0.05 was
considered significant. The TTP, PFS, and OS were esti-
mated using the Kaplan-Meier method. The data was ana-
lyzed in May 2012.
Results
Patient and treatment characteristics
The patients and their treatment characteristics are sum-
marized in Table 1. All patients included in this studye histogram of intensity modulated radiotherapy (IMRT) and
t are 50%, 60%, 70%, 80%, 90% and 100% for the 4-field technique
Table 1 Patient and treatment characteristics







(months)Dose (Gy/Fxs) CCRT After CCRT
1 M 42 Head T4N1 50/20 5-FU GEM SD Distant 7.6 12.1*
2 M 64 Head T4N0 50/20 5-FU GEM PR 7.6*
3 M 72 RM Recurrent† 50/20 5-FU GEM SD Distant 7.9 26.0*
4 F 61 Head T4N0 50/20 5-FU GEM PR 7.2*
5 M 74 Body T4N0 50/20 5-FU GEM SD Distant 2.0 9.8*
6 M 63 Tail T4N0 50/20 5-FU GEM PR Distant 6.0 9.2*
7 F 61 Celiac trunk Recurrent† 50/20 5-FU 5-FU/LV PR Distant 8.0 12.8*
8 M 66 Body T4N1 50/20 5-FU SD Local/Distant 14.6 22.7*
9 M 71 Body T4N0 50/20 5-FU GEM PR Distant 13.9 19.4*
10 M 68 Head T4N0 45/15 5-FU GEM PR Distant 8.0 20.0*
11 F 56 Celiac trunk Recurrent† 45/15 5-FU GEM PR Distant 4.9 6.9
12 F 66 Head T4N1 45/15 5-FU GEM SD 5.7
Abbreviations: RT = radiotherapy; CCRT = concurrent chemoradiation; GEM = gemcitabine; 5-FU = 5-fluorouracil; LV = leucovorin; TTP = time to progression;
PR = partial regression; SD = stable disease; RM = resection margin.
* Dead.
† Recurrent disease after curative resection.
Table 2 Grade 2 or worse acute and late toxicities
Number of patients (%)
Grade 2 Grade 3 Total
Acute toxicities
Neutropenia 2 (17%) 2 (17%) 4 (33%)
Thrombocytopenia 1 (8%) 1 (8%) 2 (17%)
Nausea/Vomiting 1 (8%) 1 (8%)
Diarrhea 1 (8%) 1 (8%)
Late toxicities
Gastric ulcer 2 (17%) 2 (17%)
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had unresectable locally advanced pancreatic cancer and
3 patients had locally recurrent disease after curative re-
section (distal pancreatectomy was performed in 2
patients and Whipple’s operation was performed in 1 pa-
tient). The PTV were 143.3 ± 5.3 cm3 in the patients
treated with 45 Gy in 15 fractions and 203.3 ± 57.4 cm3
in the patients treated with 50 Gy in 20 fractions. This
difference was statistically significant (p = 0.014). Regard-
ing the DVHs, the median delivered dose to 95% of the
GTV was 51.7 Gy (range: 48.0-58.6 Gy), and that to the
D2cc of the stomach, duodenum and small intestine was
44.5 Gy (range: 29.0-52.4 Gy). Although the D2cc of the
stomach, duodenum and small intestine was higher than
the constraint levels in 5 patients, the treatment plans
were accepted to achieve adequate tumor coverage.
Toxicities
Grade 2 acute toxicities developed in 5 patients (42%)
and grade 3 acute toxicities developed in 2 patients
(17%). Of these, 5 patients (42%) experienced grade 2 or 3
hematologic toxicities (neutropenia or thrombocytopenia)
and 2 patients (12%) experienced grade 2 gastrointestinal
toxicities (diarrhea or nausea/vomiting). In 4 patients who
experienced symptoms such as gastritis after CCRT, EGD
was performed. Of those patients, grade 2 gastric ulcer
developed in 2 patients (12%). The toxicities are summar-
ized in Table 2. The PTV was correlated marginally with
late gastrointestinal toxicities, but the relationship was not
statistically significant (p = 0.069). There was a trend to-
ward a correlation between acute or late gastrointestinal
toxicities and D2cc of the stomach, duodenum, and small
intestine, but it was not statistically significant (p = 0.08).Local response and failure-pattern
At the initial response evaluation after CCRT, partial re-
sponse (PR) and stable disease (SD) were achieved in 7
and 5 patients (58% and 42%), respectively, and none of
the patients developed progressive disease. These re-
sponse evaluations were performed using follow-up CT.
In addition, 7 patients (58%) experienced abdominal
pain at the time of diagnosis and needed to take analge-
sics for pain-control, and all of them exhibited improve-
ment of their symptoms after CCRT.
After a median follow-up of 31.1 months (range: 5.7-
36.3 months), 1 patient (8%) experienced local progres-
sion, and 9 patients (75%) experienced distant progression.
No patient experienced regional failure. The median TTP
was 8.0 months (95% CI: 7.7-8.3 months). The sites of dis-
tant failure were the liver for 4 patients, lung for 4 patients,
peritoneum for 5 patients, and bone for 1 patient. The
median PFS and OS were 7.6 (95% CI: 6.8-8.3 months) and
12.1 months (95% CI: 7.4-16.7 months), respectively.
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compared with those of previous reported studies and a sig-
nificant clinical impact could not be revealed due to the
small number of patients included in this study.
Discussion
The purpose of this study was to evaluate the technical
feasibility of an IG-IMRT involved-field technique to
perform a hypofractionated schedule in patients with lo-
cally advanced or recurrent pancreatic cancer. The hypo-
fractionation regimen used in this study was 45 Gy in 15
fractions or 50 Gy in 20 fractions, which were equivalent
to 49.6 or 53 Gy in 1.8 Gy fractions, respectively (assum-
ing an α/β ratio of 10). The CCRT was completed in
only 3 or 4 weeks, which was shorter than the 6 weeks
necessary for conventional RT. In previously reported
studies, a 40–60 Gy dose of radiation was used for con-
ventional RT along with the concurrent use of chemo-
therapy [5-15], and according to the National Cancer
Care Network guideline, a dose of 45–54 Gy of RT in
conventional fractionation with the concurrent use of
chemotherapy is considered to be standard treatment.
Gemcitabine is a chemotherapeutic agent that has
been chosen as the first-line drug for the treatment of
pancreatic cancer and has the clinical benefit of a mod-
est survival advantage over 5-FU [18]. In addition, gem-
citabine is known as a potent radiosensitizer [19,20].
Therefore, gemcitabine was combined with RT in severalFigure 2 Dose-volume histograms for GTV, duodenum, and intestine
delivered to the GTV for each treatment plan were similar, there was a larg
for the treatment plans.studies [11-15]. However, the clinical outcomes in
these studies did not reveal the advantage of gemcita-
bine based CCRT compared with 5-FU based CCRT.
Wilkowski et al. tested 3 different CCRT regimens (5-FU
based CCRT vs. gemcitabine/cisplatin based CCRT vs.
gemcitabine/cisplatin based CCRT followed by gemcita-
bine/cisplatin) [21], and concluded that RT in combin-
ation with gemcitabine/cisplatin was not more clinically
efficacious than RT with 5-FU because the median OS
was similar and grade 3/4 toxicities were more frequent in
the 2 gemcitabine/cisplatin arms. According to the study
by McGinn et al., the maximal tolerated dose of radiation
that could be administered with a concurrent full-dose
gemcitabine was 36 Gy in 2.4 Gy fractions [17]. However,
this radiation dose was not sufficient for adequate local
control. Therefore, we treated used 5-FU as the che-
motherapeutic agent along with concurrent CCRT, and
full-dose gemcitabine was used sequentially after CCRT.
In this study, we excluded the uninvolved regional
LNs from the target volume and all patients were treated
with IG-IMRT. Murphy et al. conducted a study involv-
ing highly conformal treatment fields that included only
the primary tumor plus a 1 cm margin without the re-
gional LNs, and they reported that only 5% of the
patients indicated failure in the peripancreatic LNs and
that a larger PTV may not have prevented this failure
[16]. Our results indicated that none of the patients
experienced any regional failure. The traditional 3 orfrom 4-field technique and IMRT are shown. Although the doses
e difference between the doses delivered to duodenum and intestine
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commonly used in previous studies, and there were
considerable toxicities from high dose RT when
employing these methods [15,22]. The difference be-
tween IMRT and traditional 4-field techniques is
shown in Figure 2. Although the doses delivered to the
GTV for each treatment plan were similar, there were
a large difference between the doses delivered to the
duodenum and intestine. These differences could ex-
plain our lower incidence of gastrointestinal toxicities
compared with previous studies using 3–4 fields or
conformal techniques. In a recent Federation Franco-
phone de Cancerologie Digestive/French Society of Ra-
diation Oncology (FFCD/SFRO) study, the target
volume included the primary tumor plus the unin-
volved regional LNs with a wide margin and the con-
formal RT technique was used with high dose
radiation (60 Gy) [22]. The FFCD/SFRO study did not
identify an advantage for RT on an interim analysis be-
cause of the high incidence of toxicity. Therefore, ex-
cluding uninvolved regional LNs from the target
volume for hypofractionated CCRT is deemed a proper
strategy when it is combined with effective chemother-
apy. IG-IMRT could provide adequate target coverage
and reduce the incidence of serious toxicities.
The stomach, duodenum, and small intestine adjacent
to a pancreatic mass are dose-limiting organs. If the dose
delivered to these organs was not carefully planned
according to the constraint levels or if the dose was in-
accurately delivered, then the risk of gastrointestinal
toxicities such as ulcer, bleeding, stricture, obstruction
and perforation could be increased. The incidence and
severity of gastrointestinal toxicities in this study was
thought to be acceptable compared with those in previ-
ous studies. In this study, grade 3 or worse gastrointes-
tinal and hematologic toxicity were 0% and 17%,







Cohen et al. [7] RT 59.4 Gy/5-FU+mitomycin 55 13%
Ishii et al. [8] RT 50.4 Gy/5-FU 20 15%
Kornek et al. [9] RT 55 Gy/5-FU+cisplatin 38 18%
Boz et al. [10] RT 59.4 Gy/5-FU 42 4%
Magnino et al. [12] RT 45 Gy/GEM 23 30%
Blackstock et al. [13] RT 50.4 Gy/GEM 39 41%
Okusaka et al. [14] RT 50.4 Gy/GEM 38 33%
Li et al. [15] RT 50.4-61.2 Gy/GEM 18 28%
Murphy et al. [16] *RT 36 Gy/GEM 74 11%
This study *RT 50 Gy/5-FU 10 0%
Abbreviations: PFS = progression-free survival; OS = overall survival; RT = radiothera
* Hypofractionated CCRT.than the findings of previous studies using 5-FU based
CCRT [7-10] and significantly lower than the findings of
previous studies using gemcitabine based CCRT [12-16].
This is summarized in Table 3. In addition, 2 patients
(17%) experienced medically controllable grade 2 gastric
ulcers. None of the patients experienced any grade 3 or
worse late toxicities. This is lower than 2-11% of grade 3
or worse late gastrointestinal toxicities in patients trea-
ted with gemcitabine based CCRT with conventional or
hypofractionation regimen [14-16].
At the response evaluation, 7 patients (58%) achieved
a PR, and 5 patients (42%) exhibited a SD. The treat-
ment response was determined by the reduced size of
the mass in the follow-up CT. However, the response for
a treated pancreatic mass can be underestimated be-
cause the size reduction on the anatomic imaging cannot
be perfectly assessed due to varying degrees of acute or
subacute pancreatitis or radiation-induced fibrosis. Local
progression of a primary mass may cause severe abdom-
inal pain, gastric outlet/duodenal obstruction, and bleed-
ing which adversely influence the quality of life and can
be a cause of death in many cases; therefore, control of
the primary tumor is extremely important. In this study,
1 patient (8%) experienced local progression. The major
cause of treatment failure was distant metastases, which
developed in 10 patients (83%). In addition, 6 of our
patients who experienced abdominal pain at the time of
diagnosis indicated improvement of their symptoms
after CCRT. Therefore, this hypofractionation regimen
can be considered an effective treatment for pain con-
trol and local control compared with the local failure
rate of 6-51% reported for conventional RT [3,8,10,12-15].
Because of the small number of patents included in this
study, the PFS and OS from this study could not be
compared with those of previously reported studies,
and therefore, the clinical significance of our findings
could not be demonstrated (Table 3).inal
rade 3)
Hematologic







20% NA 5.1 8.4
0% 35% 4.9 10.3
18% NA 10 14
16% 51% 6.2 9.1
39% 22% NA 12
69% 15% NA 7.9
52% 6% 4.4 9.5
28% 34% 7.1 14.5
24% 26% NA 11.2
17% 8% 7.6 12.1
py; 5-FU = 5-fluorouracil; GEM = gemcitabine; NA = not available.
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http://www.ro-journal.com/content/7/1/203In conclusion, the involved field technique and IG-
IMRT using TomoTherapy provided adequate target
coverage while sparing the surrounding normal tissues
and consequently reduced the incidence of serious
gastrointestinal toxicities and the rate of locoregional
failures. Therefore, it is feasible to perform a hypofrac-
tionated schedule in patients with locally advanced or
recurrent pancreatic cancer.
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